Plasma Partners: Coalition for Hemophilia B


The Coalition for Hemophilia B’s ( mission is to make the quality of life the focal point of treatment for people with hemophilia B and their families through education, empowerment, advocacy, and outreach. For 30 years we have driven our mission through a family-oriented approach because hemophilia affects the whole family.

Hemophilia is a disorder in which the blood does not clot properly. The two most common types, hemophilia A and hemophilia B, are caused by defective or missing proteins that are part of the clotting system, also called the coagulation cascade. In hemophilia B, the defective or missing protein is called factor IX.

Hemophilia was originally thought to be a disorder that affects primarily males, but a significant number of females are now properly being diagnosed as having hemophilia. There are several other bleeding disorders, most caused by defects in or the absence of other proteins of the clotting system. The most common of these is von Willebrand disease. Most of the others are extremely rare.

There is no cure for hemophilia B or other bleeding disorders. They are treated primarily with replacement therapies, usually clotting factor, although many new therapies are in the late stages of development. The original clotting factor products were made primarily from human plasma, although today most patients use products made through recombinant technology. However, some patients still use plasma-derived therapies.

You can find the Coalition for Hemophilia B's blog here:

News & Updates

Get the latest information on plasma through our news and updates. Featuring: Scientific discoveries, plasma supply, industry-related coverage, policy and legislation, and more!

How plasma saved lives through the ages, from 1918 to WWII to today


Both convalescent plasma and plasma-based therapies have been around for some time, though many people are still unfamiliar with their history.
Read More

Science-based policies boost plasma donation globally


Science is driving global advancements in policy and allowing more people around the world to donate plasma while ensuring the safety of donors and the plasma collected.
Read More

How plasma-based therapies treat hemophilia


Plasma has been used to treat bleeding disorders like hemophilia since the 1950s, and is still one of the most effective treatment options for patients.
Read More

GBS, CIDP, and plasma


Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare neurological disorders and plasma-based therapies are used to treat them.
Read More

FDA proposes risk-based rules for plasma and blood donations


On January 27, 2023, the U.S. Food and Drug Administration announced a draft proposal for eligibility rules for blood and blood product donation using “gender-inclusive, individual risk-based questions to reduce the risk of transfusion-transmitted HIV.”
Read More

Stiff person syndrome and plasma


SPS is a rare and progressive neurological disease. It affects one person in a million and Celine Dion is one of those people relying on plasma donation to treat the condition.
Read More
Powered By:
Mojo Creative Digital